Overview

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Assess mechanism of action of LCZ696 related to sodium excretion.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination
Valsartan